{'fraction_non_alphanumeric': 0.024106400665004156, 'fraction_numerical': 0.011637572734829594, 'mean_word_length': 5.543478260869565, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Synthetic PPARγ Agonist Troglitazone Inhibits IL-5-Induced CD69 Upregulation and Eosinophil-Derived Neurotoxin Release from Eosinophils

Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear receptor that regulates lipid metabolism. Recently, PPARγ was reported to be a negative regulator in the immune system. Eosinophils also express PPARγ, however, the role of PPARγ in eosinophil functions is not well understood. Surface expression of CD69 and eosinophil-derived neurotoxin (EDN) release are well-known activation markers of eosinophils. We investigated the effect of a PPARγ agonist on human eosinophil functions such as IL-5-induced CD69 surface expression and EDN release. IL-5 significantly induced eosinophil CD69 surface expression analyzed using flow cytometry and EDN release measured by ELISA. IL-5-induced eosinophil CD69 surface expression and EDN release were significantly inhibited by the synthetic PPARγ agonist troglitazone, and these effects were reversed by a PPARγ antagonist. The PPARγ agonist troglitazone has a potent inhibitory effect on activation and degranulation of eosinophils, and it may be a therapeutic modality for the treatment of allergic diseases.